CA 125, a high-molecular-mass glycoprotein antigenic determinant, is expressed in more than 80% of nonmucinous ovarian adenocarcinomas (1). Bast et al. (2, 3) developed a murine monoclonal antibody (0C125) that can be used to measure CA 125 immunometrically in serum. The 0C125 antibody also is used for radioimmunodetection in vivo. Radioinimunodetection in combination with the monitoring of CA 125 in serum seems to be a sensitive diagnostic tool for early detection of recurrence (4).
OC125 antibodies, CA 125 should be measured by an assay in which other antibodies are used.
CA 125, a high-molecular-mass glycoprotein antigenic determinant, is expressed in more than 80% of nonmucinous ovarian adenocarcinomas (1). Bast et al. (2, 3) developed a murine monoclonal antibody (0C125) that can be used to measure CA 125 immunometrically in serum. The 0C125 antibody also is used for radioimmunodetection in vivo. Radioinimunodetection in combination with the monitoring of CA 125 in serum seems to be a sensitive diagnostic tool for early detection of recurrence (4) .
One side effect of in vivo administration of murine antibodies is the appearance of human antibodies to the applied murine immunoglobulin (5-9). Besides possible in vivo complications, such antibodies can interfere with assay of circulating antigen (5, 10).
In a previous investigation we found in some ovarian cancer patients, after radioimmunodetection, very high concentrations of CA 125 in serum but no appropriate clinical signs of disease (4). As reported here, we examined serum samples from one of these patients for interfering components responsible for the high concentration of CA 125. Our results suggest that human anti-idiotypic anti- 
Case Report
In April 1986, a 61-year-old white woman was referred to our hospital, after a peritoneal carcinomatosis was diagnosed laparoscopically in an outer hospital. We performed a laparotomy including tumor reduction. The histological examination confirmed a solid, papillary ovarian adenocarcinoma at stage ifi, according to the FIGO-system (11). After surgery the patient underwent chemotherapy consisting of two courses of mitomycin (12 mg/m2) intraperitoneally, followed by three courses of etoposide (150 mg/m2 daily for three days) intravenously and another six courses with oral application (300 mg/rn2 daily for three days) at monthly intervals. after the third immunoscintigraphy.
Serum was also sampled from a patient with ovarian cancer metastases, who served as a control. To remove the llAMA, we coupled mouse IgG (Biogenesis) to Sepharose B4, 2 mg of IgG per milliliter of gel, as described above. We applied 0.1-mL serum samples, diluted 10-fold with Tris buffer, to 1-mL columns equilibrated with Tris buffer. After 60 mm at room temperature the columns were washed with 15 The falsely positive CA-125-like material could be purified by affinity chromatography with Protein A-Sepharose.
It was quantitatively
bound by the Protein A-Sepharose column and was accounted for in the subsequent eluate. In contrast, about 52% of the CA 125 activity of the control sample passed directly through the column, and no CA 125 activity was found in the subsequent eluate.
The CA-125-like material also was bound by anti-human-IgG Sepharose. All CA-125-like activity was adsorbed, but only 32% of the applied CA-125-like material could be accounted for in the subsequent eluate. Similarly, serum IgG was also adsorbed by the anti-human IgGSepharose, and 38% of the applied IgG could be accounted for in the eluate. The CA 125 activity of the control serum passed through the column completely, whereas all the serum IgG was absorbed (Table 1) .
Because false-positive results in immunometric assays can be due to llAMAs present in the tested specimen, we determined the llAMA titer in serum from the patient. Before the chromatographic treatment, we measured an increased HAMA titer of 7.65 mg/L. After chromatography on a column containing immobilized mouse IgG, the llAMA titer was not detectable, but the CA-125-like activity decreased only slightly.
To verify putative anti-idiotypic nature of the CA-125-like material, we studied the binding of the purified CA-125-like material to whole 0C125 antibodies in the presence of increasing concentrations of CA 125. The binding of 1251-labeled OC125 antibodies to the CA-125-like material 
